Alnylam Pharma (ALNY) Tops Q4 EPS by 32c
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $251.65 --0%
Revenue Growth %: +15.3%
Financial Fact:
Unrealized (loss) gain on marketable securities: -18.33M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Revenue Growth %: +15.3%
Financial Fact:
Unrealized (loss) gain on marketable securities: -18.33M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of ($0.28), $0.32 better than the analyst estimate of ($0.60). Revenue for the quarter came in at $24.02 million versus the consensus estimate of $13.1 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
- Franklin BSP Realty Trust (FBRT) Reiterated at Market Outperform by Citizens
- Getty Realty (GTY) Reiterated at Market Outperform by Citizens on Investment Volumes
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
